Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $88.46 Consensus PT from Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $88.46.

RARE has been the subject of a number of research reports. Wells Fargo & Company raised their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. Cantor Fitzgerald restated an "overweight" rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. JPMorgan Chase & Co. lowered their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research report on Thursday, November 21st. Finally, TD Cowen upped their target price on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a research report on Monday, October 21st.

Ultragenyx Pharmaceutical Stock Down 1.8 %

RARE traded down $0.79 during trading on Thursday, hitting $43.65. The company's stock had a trading volume of 612,851 shares, compared to its average volume of 1,340,190. The firm's 50 day moving average price is $46.41 and its two-hundred day moving average price is $49.52. The stock has a market capitalization of $4.03 billion, a price-to-earnings ratio of -6.75 and a beta of 0.58. Ultragenyx Pharmaceutical has a 12 month low of $37.02 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm's quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.23) EPS. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -6.2 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Emil D. Kakkis sold 11,727 shares of the firm's stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares of the company's stock, valued at $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.80% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of RARE. Nordea Investment Management AB raised its stake in shares of Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock valued at $1,658,000 after purchasing an additional 3,246 shares during the period. Principal Financial Group Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 740.0% during the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after buying an additional 76,150 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $83,000. Geode Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock valued at $87,296,000 after acquiring an additional 65,623 shares in the last quarter. Finally, M&T Bank Corp boosted its position in Ultragenyx Pharmaceutical by 8.1% during the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock worth $388,000 after acquiring an additional 525 shares during the last quarter. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.